These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22101805)

  • 21. Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.
    Hall JJ; Sriram M; Strecker TE; Tidmore JK; Jelinek CJ; Kumar GD; Hadimani MB; Pettit GR; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5146-9. PubMed ID: 18710804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2.
    Pettit GR; Quistorf PD; Fry JA; Herald DL; Hamel E; Chapuis JC
    J Nat Prod; 2009 May; 72(5):876-83. PubMed ID: 20161135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
    Hori K; Saito S; Nihei Y; Suzuki M; Sato Y
    Jpn J Cancer Res; 1999 Sep; 90(9):1026-38. PubMed ID: 10551334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.
    Monk KA; Siles R; Hadimani MB; Mugabe BE; Ackley JF; Studerus SW; Edvardsen K; Trawick ML; Garner CM; Rhodes MR; Pettit GR; Pinney KG
    Bioorg Med Chem; 2006 May; 14(9):3231-44. PubMed ID: 16442292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
    Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
    Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062).
    Hori K; Saito S; Sato Y; Akita H; Kawaguchi T; Sugiyama K; Sato H
    Eur J Cancer; 2003 Sep; 39(13):1957-66. PubMed ID: 12932676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
    Siles R; Ackley JF; Hadimani MB; Hall JJ; Mugabe BE; Guddneppanavar R; Monk KA; Chapuis JC; Pettit GR; Chaplin DJ; Edvardsen K; Trawick ML; Garner CM; Pinney KG
    J Nat Prod; 2008 Mar; 71(3):313-20. PubMed ID: 18303849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
    Hori K; Saito S; Sato Y; Kubota K
    Med Sci Monit; 2001; 7(1):26-33. PubMed ID: 11208488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combretastatins D-3 and D-4, new macrocyclic lactones from Getonia floribunda.
    Vongvanich N; Kittakoop P; Charoenchai P; Intamas S; Danwisetkanjana K; Thebtaranonth Y
    Planta Med; 2005 Feb; 71(2):191-3. PubMed ID: 15729632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
    Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
    Kanthou C; Tozer GM
    Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4.
    Guan Q; Yang F; Guo D; Xu J; Jiang M; Liu C; Bao K; Wu Y; Zhang W
    Eur J Med Chem; 2014 Nov; 87():1-9. PubMed ID: 25233100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the field of tubulin polymerization inhibitors.
    Prinz H
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):695-708. PubMed ID: 12503216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OMA1520 and OMA1774, novel 1,2,4-triazole bearing analogs of combretastatin A-4, inhibit hepatocellular carcinoma: Histological and immunohistochemical studies.
    Nofal AE; Shatla IM; Abdelhafeez DA; Mustafa M; Aly OM
    Biomed Pharmacother; 2021 Jun; 138():111417. PubMed ID: 33752057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
    Chaplin DJ; Pettit GR; Hill SA
    Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
    Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
    Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
    McGown AT; Fox BW
    Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of isoerianin analogues as promising anticancer agents.
    Messaoudi S; Hamze A; Provot O; Tréguier B; Rodrigo De Losada J; Bignon J; Liu JM; Wdzieczak-Bakala J; Thoret S; Dubois J; Brion JD; Alami M
    ChemMedChem; 2011 Mar; 6(3):488-97. PubMed ID: 21360820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.
    Chaplin DJ; Pettit GR; Parkins CS; Hill SA
    Br J Cancer Suppl; 1996 Jul; 27():S86-8. PubMed ID: 8763854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
    Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
    Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.